This is a StreetInsider.com Premium Only Page

Orexigen Therapeutics (OREX) – Press Releases

Apr 23, 2018 11:30 AM Orexigen Therapeutics, Inc. Enters Agreement for Sale of Company

Mar 12, 2018 01:08 AM Orexigen Therapeutics, Inc. Plans For Near-term Sale Using Structured Process Through Chapter 11 Of U.S. Bankruptcy Code

Nov 13, 2017 04:01 PM Orexigen Therapeutics Announces Third Quarter 2017 Financial Results

Nov 13, 2017 08:08 AM Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Merck KGaA, Darmstadt, Germany for Contrave in Latin America

Oct 31, 2017 06:57 PM Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2017 Financial Results on November 13, 2017

Oct 13, 2017 02:40 PM Orexigen Announces Favorable Decision from U.S. District Court in Patent Litigation, Confirming Exclusivity for Contrave Through 2030

Oct 12, 2017 08:57 PM Orexigen Therapeutics to Provide Business Update at the 2017 BIO Investor Forum

Sep 26, 2017 05:13 PM Orexigen Therapeutics Launches Next Stage of a Dynamic Campaign to Educate Consumers About Contrave®

Sep 13, 2017 05:21 PM Orexigen Therapeutics to Provide Business Update at the 2017 Cantor Fitzgerald Global Healthcare Conference

Aug 29, 2017 09:25 AM Orexigen Therapeutics to Speak at Upcoming Investor Conferences

Aug 8, 2017 04:01 PM Orexigen Therapeutics Announces Second Quarter 2017 Financial Results

Aug 7, 2017 07:10 AM Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel GmbH for Mysimba™ in Germany, France and Austria

Jul 26, 2017 08:50 AM Orexigen Therapeutics Announces Expansion of Distributorship Agreement with Biologix FZCO for Contrave® (naltrexone HCl / bupropion HCl extended release) to Egypt

Jul 25, 2017 04:30 PM Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2017 Financial Results on August 8, 2017

Jul 10, 2017 12:01 PM Orexigen Announces Presentation of Data for OREX-1019 and OREX-1038, Preclinical Candidates for the Treatment of Chronic Pain with Reduced Addiction Liability and the Treatment and Management of Opioi

May 16, 2017 04:10 PM Orexigen Announces Activities at European Congress on Obesity 2017

May 9, 2017 04:01 PM Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017

May 2, 2017 04:57 PM Orexigen Therapeutics to Provide Business Update at the 2017 Bank of America Merrill Lynch Healthcare Conference

May 2, 2017 03:00 AM Navamedic ASA: Enters into partnership agreement with Orexigen Therapeutics for Nordic launch of Mysimba®

May 2, 2017 03:00 AM Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Five Nordic Countries

Apr 25, 2017 06:05 PM Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2017 Financial Results on May 9, 2017

Apr 25, 2017 01:55 AM Orexigen Therapeutics Announces New Drug Submission for Contrave© in Canada

Mar 28, 2017 04:21 PM Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016

Mar 27, 2017 06:03 PM Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Bruno Farmaceutici S.p.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Italy

Mar 7, 2017 08:56 PM Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Year End 2016 Financial Results on March 28, 2017

Feb 7, 2017 04:40 PM Orexigen Therapeutics to Speak at Upcoming Investor Conferences

Jan 25, 2017 07:40 AM Orexigen Therapeutics Announces Spanish Launch of Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Partnership with Laboratorios Farmacéuticos Rovi, S.A.

Jan 6, 2017 08:05 AM Orexigen Therapeutics Announces Publication of Contrave® (naltrexone HCl and bupropion HCl extended-release tablets) Real-World Study Results in "Obesity"

Jan 5, 2017 07:50 AM Orexigen Therapeutics Highlights Key Business Priorities for 2017

Jan 3, 2017 08:29 PM Orexigen Therapeutics Launches "Brains Behind Weight Loss," a Dynamic Patient Focused Campaign to Educate Consumers on the Role of the Brain in Weight Loss

Dec 19, 2016 08:10 AM Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Biologix FZCO for Contrave® (naltrexone HCl / bupropion HCl prolonged release) for Ten Countries in the Middle Eas

Dec 19, 2016 07:40 AM Orexigen Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference 2017

Dec 8, 2016 07:25 AM Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Consilient Health Ltd. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in the UK and Ireland

Nov 16, 2016 04:15 PM Orexigen Announces Presentation of Data for OREX-1019, a Preclinical Candidate for the Treatment and Management of Drug Addiction

Nov 8, 2016 07:30 AM Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant for Contrave® (naltrexone HCl / bupropion HCl extended release) in Australia and New Zealand

Nov 3, 2016 04:01 PM Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2016

Nov 2, 2016 04:30 PM Orexigen Therapeutics to Present at 25th Annual Credit Suisse Healthcare Conference

Oct 21, 2016 09:00 AM Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2016 Financial Results on November 3, 2016

Sep 7, 2016 04:10 PM Orexigen Therapeutics to Speak at the Rodman & Renshaw 18th Annual Global Investment Conference

Sep 7, 2016 04:10 PM Orexigen Therapeutics to Speak at the Rodman & Renshaw 18th Annual Global Investment Conference

Aug 30, 2016 08:00 AM Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Canada for Contrave® (naltrexone HCl / bupropion HCl extended release)

Aug 30, 2016 08:00 AM Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Canada for Contrave® (naltrexone HCl / bupropion HCl extended release)

Aug 4, 2016 04:01 PM Orexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2016

Aug 1, 2016 08:31 AM Orexigen Completes Acquisition of All U.S. Rights to Contrave® and Launches U.S. Sales Organization

Aug 1, 2016 08:30 AM Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Laboratorios Farmacéuticos Rovi, S.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Spain

Jul 21, 2016 04:10 PM Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2016 Financial Results on August 4, 2016

Jul 8, 2016 04:02 PM Orexigen Therapeutics Announces Stockholder Approval of All Proposals at 2016 Annual Meeting and Reverse Stock Split

Jun 22, 2016 04:30 PM Orexigen Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jun 8, 2016 04:10 PM Orexigen Therapeutics Announces Promotions of Tom Cannell to COO and Jason Keyes to CFO

Jun 8, 2016 09:00 AM Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave® Patent Litigation